Posts by Saul Richmond

Saul is PharmSource’s Director of Market Intelligence. He brings over 15 years of experience in market analysis, having worked in business intelligence roles at Evaluate Pharma, Cardinal Health (now Catalent) and Abbott Laboratories. Prior to that, he was a Post-doctoral fellow in Neuropharmacology at the Universities of Birmingham and Bristol.  Saul holds an MSc (Neuroscience) from the Institute of Psychiatry (King’s College London) and a D.Phil in Neuropharmacology from the University of Oxford.

Large Molecule API Sector Becomes Increasingly Crowded as Peregrine Changes Focus

Competition within the 2,000-5,000 L biomanufacturing segment is set to intensify as Peregrine Pharmaceuticals (Tustin, Calif., USA) announced its transition to a dedicated CDMO from an excess capacity player. The company announced the move during the company’s quarterly conference call. Subsequently, Mark Bamforth, currently Brammer Bio (Lexington, Mass., USA) CEO and president, was appointed to […]

Learn more

CDMOs Buttressed by Resilient Emerging Biopharma Sector

Publicly traded emerging biopharmaceutical companies increased their research and development (R&D) expenditure in the second quarter of 2017, reaching almost $3.9 billion, 45% greater than the spending level seen in the second quarter of 2015 (see Figure 1, below). Although the total R&D expenditure of emerging biopharma companies (around $15 billion annually) is a fraction […]

Learn more

Bio/Pharma Financing and Drug Approvals Bounce Back in 2017

The bio/pharma sector enjoyed a healthy first half of the year, as several key metrics rebounded strongly from a disappointing 2016. The sector raised $18.1 billion in the first six months of the year, more than double the figure seen for the same period last year, although 12% lower than the record amount recorded in […]

Learn more

Venture Capital Funding Confirms Transition to Large Molecule Assets

As the major source of funding for early stage companies, the Venture Capital (VC) sector can be viewed as a window into tomorrow’s therapies. Although absolute VC spend on Research and Development (R&D) is dwarfed by that of the Global Pharmaceutical sector, the overall importance of early stage funding is critical for a number of […]

Learn more

Big Pharma Capex Continues to Grow, but Rate Slows

Spending by global bio/pharmaceutical companies on new plant and equipment grew by an average of 2.7% in 2016, compared to sales growth of 4.4% (see Figure 1, below). This is the first year in recent times that revenue growth has outpaced capex growth. Moreover, the increase in capital expenditure represented a significant decline from the […]

Learn more

2016 Results Summary: A Rising Tide Lifts All Contract Service Boats

The Contract Development and Manufacturing Organization (CDMO) sector enjoyed a strong 2016, with all components reporting robust, albeit uneven, growth. Early-stage companies posted especially impressive results, bolstered by generous external funding, and the API sector continued its recent recovery, especially in the small molecule space (see Figure 1, below). The impressive top line results do, […]

Learn more

Is R&D Productivity Improving?

In the past few years, approvals of new drugs have reached levels not seen for decades. The superficial reasons for this are clear: a combination of benign financial market conditions that have enabled companies to raise substantial amounts of cash, and regulatory authorities in Europe and the US that are committed to ensuring that novel […]

Learn more

Epirus Bankruptcy Underscores Biosimilar Challenges

The recent bankruptcy filing of Epirus Pharmaceuticals, an early stage company developing biosimilars, is a stark reminder of the risks inherent in biosimilar drug development. The company had previously shed 40% of its workforce and ceased late-stage development of its lead asset, a biosimilar version of Johnson & Johnson’s Remicade, but was attempting to maintain […]

Learn more

Global Bio/pharma Continues to Spend on PP&E

Global bio/pharma companies continued to invest heavily in new capital assets in 2015. Capital expenditure (capex) by the largest US and European bio/pharma companies experienced robust growth in 2015. Analysis of 21 of the top 25 bio/pharma companies (by revenue) revealed that total spend on property, plant and equipment grew by 12.1% to $21.7 billion […]

Learn more

European Clinical Pipeline Activity

Until the recent downturn in external financing for early stage biopharma companies, the past couple of years had witnessed something of a renaissance in biopharma funding, led as usual, by the United States. The positive mood had spread beyond the US, and this was reflected in a significant increase in pipeline activity emanating from companies […]

Learn more